PLSE
Pulse Biosciences, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
19.22
P/S
4467.85
EV/EBITDA
-20.43
DCF Value
$1.06
FCF Yield
-3.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-204.3%
Operating Margin
-21982.6%
Net Margin
-20794.6%
ROE
-73.5%
ROA
-78.5%
ROIC
-85.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $264.0K | $-17.4M | $-0.26 |
| FY 2025 | $350.0K | $-72.8M | $-1.08 |
| Q3 2025 | $86.0K | $-19.4M | $-0.29 |
| Q2 2025 | $0.00 | $-19.2M | $-0.28 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.69
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.